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Edited by Peter BrzezinskiAbstract This study was designed to investigate inducible
intrinsic resistance against lactoferricin B in Staphylococcus
aureus. Serial passage of seven S. aureus strains in medium with
increasing concentrations of peptide resulted in an induced resis-
tance at various levels in all strains. The induced resistance was
unstable and decreased relatively rapidly during passages in pep-
tide free medium but the minimum inhibitory concentration re-
mained elevated after thirty passages. Cross-resistance to
penicillin G and low-level cross-resistance to the antimicrobial
peptides indolicidin and Ala3,13,18-magainin was observed. No
cross-resistance was observed to the human cathelicidin LL-37.
In conclusion, this study shows that S. aureus has intrinsic resis-
tance mechanisms against antimicrobial peptides that can be
induced upon exposure, and that this may confer low-level
cross-resistance to other antimicrobial peptides.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Antimicrobial peptide1. Introduction
The development of resistance to multiple antimicrobial
agents in several important bacterial pathogens has lead to
the search for new antimicrobial agents with novel bacterial
targets. Cationic antimicrobial peptides have been introduced
as a new source of such potential antimicrobial agents [1,2].
Antimicrobial peptides are part of the innate immune system
in multicellular organisms, including humans, through the di-
rect killing of microbes and/or immunomodulatory functions
such as upregulation and downregulation of genes, enhanced
antibody response, chemotactic activity and modulation of
inﬂammation [3,4].
The antibacterial mode of action of antimicrobial peptides
has been extensively studied and shows a wide range of eﬀects
from interaction with the membrane to speciﬁc eﬀects on intra-
cellular targets (see reviews [5–7]). Currently, diﬀerent antimi-
crobial peptides are in late clinical trials as treatment of
various infections [8,9].*Corresponding author. Fax: +47 77 62 70 15.
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doi:10.1016/j.febslet.2005.05.017In Staphylococcus aureus several diﬀerent resistance mecha-
nisms to antimicrobial peptides have been described: (I) mod-
iﬁcation or blocking of teichoic acid [10,11], (II) alterations in
the cytoplasmic membrane [12,13], (III) involvement of prote-
ases [14,15], (IV) defective electron transport chain [16–18] and
(V) involvement of bacterial stress response system [19]. Devel-
opment of resistance by the use of antimicrobial peptides as
antimicrobial agents is largely unknown. A worst case scenario
is development of cross-resistance to human antimicrobial
peptides [20]. It is more diﬃcult to develop resistance to anti-
microbial peptides in vitro than to for instance norﬂoxacin
or gentamicin [21,22] and no experimental evidence for
cross-resistance has so far been reported.
This study was aimed to test the hypothesis that S. aureus
possess intrinsic resistance mechanisms that are inducible un-
der exposure to antimicrobial peptides. Lfcin B consists of
amino acid 17–41 from the N-terminal of bovine lactoferrin,
and is generated by pepsin cleavage [23]. It has activity against
a wide range of microorganisms, including viruses, protozoa,
fungi, Gram-negative and Gram-positive bacteria [23–28].
Lfcin B is in preclinical trials for antifungal infections [9]
and Lfcin B and other mammalian lactoferricin peptides have
been used as templates for the development of more active
antimicrobial peptides [29].2. Materials and methods
2.1. Peptides and antibiotics
Lactoferricin B 17-41 (Lfcin B) was prepared by pepsin digestion of
bovine lactoferrin at the Centre for Food Technology. (Queensland,
Australia). Indolicidin and LL-37 were synthesised at the University
of Tromsø, Department of Biochemistry as previously described [30].
Ala3,13,18-magainin, chloramphenicol, dicloxacillin sodium monohy-
drate, erythromycin, fusidic acid, rifampicin and clindamycin hydro-
chloride were purchased from Sigma–Aldrich Norway (Oslo,
Norway). Penicillin G was obtained from Panpharma SA (France)
and gentamicin from Invitrogen Ltd (Paisley UK). Bacitracin and bac-
itracin-Zn was obtained from Alpharma (Oslo, Norway).
2.2. Bacterial strains
S. aureus ATCC 25923 was used as a reference strain. Six clinical S.
aureus strains were obtained from patient samples of pus sent to the
Department of Medical Microbiology, University Hospital of North
Norway, as previously described [14]. 2% Bacto peptone water
(BPW) (Difco, Detroit, USA) was used as growth medium for all
strains. For LL-37 anion-exchanged MH-broth was used for the
MIC testing.ation of European Biochemical Societies.
Fig. 1. Induction of resistance to Lfcin B. The bars indicate ±S.D.
Table 1
MIC to Lfcin B, indolicidin (Indo), ala3,13,18-magainin (Ala-M), LL-37
and penicillin G (PenG) before and after induction of resistance
Strain Antimicrobial agent, MIC (lg/ml)
Lfcin B Indo Ala-M LL-37 PenG
ATCC 25923 20 14 10 20 <0.06
ATCC 25923-i 100 20 17.5 18 <0.06
ATCC 25923-h 600 \ \ \ \
ATCC 25923-r 1000 \ \ \ \
63978 20 12 10 20 16
63978-i 95 20 15 16 64
63978-h 200 \ \ \ \
64074 20 12 7.5 \ <0.06
64074-i 85 24 15 \ <0.06
39909 30 12 7.5 14 24
39909-i 290 28 15 16 112
39909-h 210 \ \ \ \
64259 30 14 7.5 \ <0.06
64259-i 80 24 15 \ <0.06
63973 20 14 9 \ 0.375
63973-i 40 20 15 \ 8
63643 20 12 7.5 20 <0.06
63643-i 180 24 15 16 0.125
63643-h 120 \ \ \ \
The MIC values are presented as median values. MIC values that are
two or more times higher and at least two or more titration steps
higher than the wild-type bacteria are indicated in bold.
\, Not tested; -i, induced bacteria after the primary induction of 9
passages; -h, -i strains further induced in medium with Lfcin B up to
1000 lg/ml; -r, rapidly induced bacteria with four concentrations of
Lfcin B.
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The minimum inhibitory concentration (MIC) was determined
using a standard broth microdilution technique as previously de-
scribed [10]. The MIC was determined as the lowest concentration
where no visible growth occurred. For determination of the MIC
in the presence of protease inhibitors, the protease inhibitor cocktail
set II (Calbiochem CA, USA), was added to the assay according to
Ulvatne et al. [14]. Resistant bacteria were taken directly from the
frozen culture to minimise a possible loss of induced resistance by
incubation without the presence of Lfcin B. To exclude diﬀerences
in the MIC due to testing directly from frozen culture the wild-type
ATCC 25923 strain was tested directly from frozen culture and from
overnight culture. No diﬀerence in MIC was observed between the
two testing methods. All assays were performed in duplicate and
on at least two separate occasions. The MIC assay was performed
with more titration steps than just double dilutions to more accu-
rately determine the MIC. The MIC values are presented as the med-
ian value. Induced resistance and cross-resistance was deﬁned as
bacteria with MIC values at least two or more titration steps higher
than the MIC of the wild-type bacteria.
2.4. Serial passage
Serial passage was initiated from overnight cultures grown to expo-
nential growth phase and added to medium containing Lfcin B (ﬁnal
bacterial concentration of approximately 1.0 · 106 CFU/ml). The bac-
teria were incubated overnight at 37 C and an aliquot was trans-
ferred to a new tube with a higher concentration of Lfcin B.
Concentrations used were 10, 16, 20, 25, 30, 60, 80, 100, and
200 lg/ml in the primary induction. The four resistant strains with
the highest MIC after the primary induction were further passed in
medium with increasing concentrations of Lfcin B (500 and
1000 lg/ml) (strains designated -h). To investigate if the resistance
could be rapidly induced, the ATCC 25923 strain was passed through
four passages with Lfcin B (0–100–200–500–1000 lg/ml). The remain-
ing culture at each step was harvested by centrifugation at 3000 · g.
The pellet was resuspended in brain heart infusion broth (Oxoid,
Hampshire, England) supplemented with either glycerol (Merck,
Darmstadt, Germany) or dimethyl sulphoxide (Sigma–Aldrich) and
frozen immediately at 70 C. The MIC was determined at each step
as described above.
Based upon the results during the primary induction of resistance,
ﬁve induced strains were selected, and the stability of the induced resis-
tance was determined by serial passages in medium without Lfcin B.
2.5. Measurement of protease activity
Extracellular protease activity of the bacteria was determined as pre-
viously described [31,32].
2.6. Growth characteristics on solid agar
Both the wild-type and induced bacteria were spread on human
blood agar plates (Oxoid) and PDM Antibiotic sensitivity medium II
(AB Biodisk, Sweden) and incubated at 37 C overnight. Colony mor-
phology, pigmentation and hemolysis were assessed.
2.7. Electron microscopy and immunogold labelling
Electron microscopy and immunogold labelling was performed on
the ATCC 25923 wild-type strain, ATCC 25923-i, ATCC 25923-h,
the wild-type clinical strain 39909 and 39909-i as described previously
[33]. The bacteria were exposed to 20 lg/ml Lfcin B for 30 min at
37 C.3. Results
3.1. Induction of resistance
All the S. aureus strains had an MIC between 20 and
30 lg/ml before the induction (Fig. 1 and Table 1). The pri-
mary induction resulted in induced resistance at various levels
in all strains tested. (Fig. 1 and Table 1, strains designated -i).
Four resistant strains were further passed in medium with
increasing concentrations of Lfcin B up to 1000 lg/ml (strainsdesignated -h, Table 1). In ATCC 25923-h and 63978-h, the
MIC increased further from 100 to 600 lg/ml and from 95 to
200 lg/ml, respectively. In strains 39909-h and 63643-h the
MIC decreased during further passages from 290 to 210 lg/
ml and from 180 to 120 lg/ml, respectively.
To investigate if resistance could be rapidly induced, the
ATCC 25923 strain was exposed to four passages in medium
with Lfcin B (Table 1; strain designated ATCC 25923-r).
Under this induction the MIC increased from 30 to
1000 lg/ml.
Fig. 2. Stability of induced resistance to Lfcin B in four resistant
strains after the primary induction and the ATCC 25923-h strain. The
bars indicate ±S.D.
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The stability of the induced resistance was tested by serial
passage of four resistant strains and the ATCC 25923-h strain
in medium without Lfcin B for thirty passages (Fig. 2). After 5
passages, the MIC of the resistant clinical strains and ATCCFig. 3. Electron micrographs of the wild-type and the resistant bacteria. (A) S
25923 exposed to 20 lg/ml Lfcin B for 30 min. Bar: 100 nm. (C) ATCC
Representative electron micrograph of ATCC 25923-h bacterial cells expose25923-h decreased by 2–3 fold. In the ATCC 25923-i strain
the MIC was unchanged after 5 passages. With further pas-
sages the MIC decreased in all strains. In the ATCC 25923-h
strain the MIC stabilised at a high level, 4–10 fold higher than
the wild-type, while in the other strains the MIC stabilised at a
lower level, but still elevated compared to wild-type bacteria.3.3. Growth characteristics on solid agar and involvement of
proteases
We have previously described that proteases are involved in
the susceptibility to Lfcin B in both Escherichia coli and S. aur-
eus [14]. To investigate if the induced resistance could be due to
an upregulation of a protease, the MIC was determined in the
presence of protease inhibitors in four i-strains and the ATCC
25923-h strain. The MIC was reduced in all strains when the
protease inhibitors were present, but there were no signiﬁcant
diﬀerences between wild-type and resistant bacteria (data not
shown). Protease activity in the bacterial supernatant was also
measured before and after induction. The extracellular prote-
ase activity was reduced in all but one i-strain; however the dif-
ference in activity was not signiﬁcant between the wild-type
and resistant bacteria (data not shown). Both the wild-type. aureus ATCC 25923 not exposed to Lfcin B. Bar: 200 nm. (B) ATCC
25923-h exposed to 20 lg/ml Lfcin B for 30 min. Bar: 200 nm. (D)
d to 20 lg/ml Lfcin B for 30 min. Bar: 200 nm.
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grown on diﬀerent solid agar. No diﬀerence was observed with
regard to colony morphology, pigmentation or hemolysis (data
not shown).3.4. Electron microscopy and immunogold labelling
Electron microscopy and immunogold labelling were per-
formed with the ATCC 25923 wild-type strain, ATCC
25923-i, ATCC 25923-h, the wild-type clinical strain 39909
and 39909-i, to study morphological changes and to determine
the location of Lfcin B. The bacteria were exposed to 20 lg/ml
Lfcin B for 30 min. Lfcin B crossed the cytoplasmic membrane
and entered the cytoplasm of both the wild-type and resistant
bacteria (Fig. 3). Morphological changes like formation of
mesosomes, separation of the membrane from the cell wall
and condensation of DNA was observed in both the wild-type
and resistant bacteria exposed to Lfcin B.3.5. Cross-resistance
Resistant i-strains were tested for cross-resistance to three
other antimicrobial peptides and several antimicrobial agents
(see Table 1). Low-level cross-resistance to indolicidin and
Ala3,13,18-magainin was observed in three and four i-strains,
respectively. Also, the MIC to these two antimicrobial peptides
was elevated in all i-strains. No cross-resistance was observed to
the human cathelicidin LL-37. Cross-resistance to penicillin G
was observed in three strains. Two of these strains (63978-i
and 39909-i) were resistant to penicillin G before the induction,
but a further increase in MIC was observed after the induction.
Wild type strain 63973was sensitive to penicillinGwhile 63973-i
became resistant after the induction.No cross-resistancewasob-
served with the other antimicrobial agents tested.4. Discussion
Since the discovery of antimicrobial peptides there has been
an increasing interest in the potential of these peptides as anti-
microbial agents for therapeutic use. Along with this interest,
the concern about the consequences of possible development
of resistance to antimicrobial peptides has emerged [20]. The
results presented here indicate that resistance to Lfcin B is pos-
sible to induce in S. aureus, and this resistance also aﬀects the
susceptibility to other antimicrobial peptides and agents.
The resistance observed is rapidly inducible, strain depen-
dent and unstable over time. Induction of resistance may be
a result of several metabolic and/or genetic changes in the bac-
terial population. These changes may involve several resistance
mechanisms. The mode of action of Lfcin B suggests a multi-
hit mode of action involving both membrane and intracellular
targets [10,33–36]. Modiﬁcation of the initial binding sites of
the bacteria [10,11] and/or alterations in the cytoplasmic mem-
brane [12,13] would prevent the peptide from reaching its tar-
get. However, the electron microscopy shows that Lfcin B is
located in the cytoplasm of both wild-type and resistant
strains. Hence, no signiﬁcant exclusion of peptide may explain
the induced resistance observed here.
No diﬀerence in the susceptibility to Lfcin B in the presence
of protease inhibitors was observed between the wild-type and
induced strains and no increase in extracellular proteolytic
activity was observed in the same strains. The electron micros-copy images also indicate that no increased proteolytic degra-
dation is taking place in the resistant strains. The induction of
resistance in S. aureus is most likely not due to the activity of
proteolytic degradation alone.
It could be speculated that since Lfcin B has a multi-hit
mode of action the development of resistance could occur in
several steps related to the diﬀerent actions of Lfcin B on the
bacteria. Bacteria exposed to a rapid induction resulted in a
high MIC equal the concentration used during the induction
(strain ATCC 25923-r) while further induction of the -i strains
resulted in lower MIC values than the ﬁnal concentration used
in the induction (-h strains). There might be one rapid and one
adaptive resistance mechanism. The rapid resistance mecha-
nism might be through activation of a stress response in the
bacteria. The involvement of a stress response protein in the
resistance to Lfcin B and cathepsin G has previously been
shown [14,19], arguing for an activation of the bacterial stress
system as a possible resistance mechanism. Also, suggesting
diﬀerent resistance mechanisms is the observation that there
are diﬀerences in the stability of the induced resistance. The in-
duced resistance in the ATCC 25923-h strain remained stable
at a high level while the induced resistance arising from the pri-
mary induction almost normalised without selective pressure.
A defective electron transport chain, a characteristic of S.
aureus small colony variants (SCV), has been described previ-
ously as a mechanism of resistance to antimicrobial peptides
including Lfcin B [16–18]. It could be speculated that Lfcin
B during the passages induces an unstable SCV phenotype
which reverts without the selective pressure of the peptide.
However, no changes in colony morphology, hemolysis or
pigment was observed between the induced strains and the
wild-type bacteria when grown on diﬀerent agar suggesting
that no major metabolic change, characteristic for SCVs, has
occurred.
Low-level cross-resistance to the antimicrobial peptides ind-
olicidin and Ala3,10,18-magainin, and cross-resistance to peni-
cillin G indicates that the resistance mechanism in S. aureus
to Lfcin B aﬀects the susceptibility both to other antimicrobial
peptides and to conventional antimicrobial agents. The cross-
resistance to penicillin G was only observed in 3 out of the 7
strains tested (Table 1), suggesting that the eﬀect could be
strain dependent. Lfcin B inhibits autolysin (Atl) induced lysis
[16] which is required for the lytic activity of penicillin G [37].
It could be speculated that Lfcin B induces changes in the Atl
function or regulation of the atl gene resulting in cross-resis-
tance to penicillin G. Autolysis is also inhibited by heat shock
[38], and previous observations have shown that the heat shock
induced protein DegP/HtrA is involved in the susceptibility to
Lfcin B in E. coli [14]. Heat shock proteins could therefore be
involved in the resistance to Lfcin B and penicillin G. Bovine
lactoferrin, from which Lfcin B is derived, inhibits b-lactamase
production [39] and Lfcin B might also possess this property.
The mechanism(s) for the low-level cross-resistance to the
antimicrobial peptides indolicidin and the magainin-2 ana-
logue also remains unclear. Due to the low-level of cross-resis-
tance, the mechanism(s) for this might involve the cytoplasmic
membrane, which is a likely common target for the antimicro-
bial peptides. However, both indolicidin and Lfcin B inhibits
macromolecular synthesis [36,40], and a common intracellular
resistance mechanism could also be possible.
In conclusion, this study shows that resistance to the antimi-
crobial peptide Lfcin B can be readily induced in S. aureus, and
Ø. Samuelsen et al. / FEBS Letters 579 (2005) 3421–3426 3425that the resistance mechanism(s) involved also results in low-
level cross-resistance to two other antimicrobial peptides and
cross-resistance to penicillin G. The mechanism(s) for the in-
duced resistance is currently not elucidated, but the results im-
ply that the resistance mechanisms may be as diverse as the
mode of action. Further experiments are ongoing to investigate
the resistance mechanism, and these studies may identify pos-
sible targets for new antimicrobial agents.
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